Abatacept Intravenous (Iv) Powder 250 mg/vial Suppliers & Bulk Manufacturers
Available Forms: Intravenous (IV) Powder
Available Strengths: 250 mg/vial
Reference Brands: Orencia(US & EU)
Category: Arthritis
Abatacept inhibits T-cell activation by blocking CD80/CD86 co-stimulatory signals, reducing inflammation in autoimmune diseases. Benefits include rapid symptom relief, slowed disease progression, improved joint function, and convenient IV administration. It offers effective disease control with a good safety profile when monitored properly.
Product Description:
Abatacept IV powder is approved in both the EU and US for rheumatoid arthritis and other autoimmune diseases. In the EU, brands like Orencia are regulated by EMA, with dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on comprehensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed dossiers for approval and continuous safety monitoring. For expert support with regulatory dossiers, registration, and compliance, visit PharmaTradz. We streamline market access for abatacept IV products, ensuring adherence to European and US standards for safe, effective biologic therapies, helping you navigate complex regulatory landscapes efficiently.
Abatacept Intravenous (Iv) Powder — third party manufacturing & bulk supply
Abatacept Intravenous (Iv) Powder 250 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Abatacept Intravenous (Iv) Powder listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Abatacept Intravenous (Iv) Powder →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Abatacept is used to treat autoimmune conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It reduces inflammation and helps prevent joint damage by inhibiting T-cell activation.
Abatacept is a recombinant fusion protein composed of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1. This engineered protein blocks costimulatory signals required for full T-cell activation.
The primary trade name for abatacept is Orencia.
Orencia (abatacept) is marketed by Bristol Myers Squibb.
The generic name is abatacept.
The brand name is Orencia.
Orencia is manufactured in approved Bristol Myers Squibb facilities, primarily in the United States and at additional licensed manufacturing sites in Europe for global supply.
Related Products
Pegloticase Injecatble
Strength:
8 mg/1.2 mL vial
Form: Injectable (IV solution)
Reference Brands: Krystexxa (US)
View Details
Febuxostat Tablets
Strength:
40 mg, 80 mg
Form: Oral Tablets
Reference Brands: Uloric(EU & US)
View Details
Allopurinol Tablets
Strength:
100 mg, 300 mg
Form: Oral Tablets
Reference Brands: Aloprim(US & EU)
View DetailsQuick Response Guaranteed | Verified Suppliers
